At the beginning of the study, and every week thereafter, patients were evaluated through sputum culture, a sputum smear for acid-fast bacilli (AFB), WBC count, hemoglobin level measurement, hematocrit, and measurement of the levels of total serum cholesterol, high-density lipoproteins (HDLs), low-density lipoproteins (LDLs), triglycerides, glucose, albumin, and globulins. Respiratory symptoms (ie, cough, sputum production, and dyspnea) were rated by the patient on a visual analog scale with a range of 0 to 10, with the assistance of one of the investigators (C.P.G.). Monitoring of the potential side effects of antitubercular drugs was performed using the usual clinical evaluation and laboratory tests recommended by the International Union Against Tuberculosis and Lung Diseases.1 Thus, besides the weekly measurement of liver enzyme levels, symptoms suggestive of drug toxicity, such as jaundice, hepatomegaly, abdominal pain, fever, anorexia, nausea, vomit, impaired vision, paresthesia, myalgias, muscle weakness, ataxia, pruritus, rash, anemia, and osteoarticular pain, were evaluated daily. The susceptibility of mycobacteria to antitubercular drugs was also tested at the beginning of the study, with the first sputum culture. Body mass index calculation, tuberculin skin test (purified protein derivative, 2 IU), and chest radiography (posteroanterior and left lateral views) were performed at the beginning and the end of the study. A percentage of radiologic improvement, primarily based on the extension of lesions, was independently calculated by two of the authors (C.P.G. and H.V.V.), who were blinded to any identifying information that was present on the chest radiograph.